A bone drill is a nasty-sounding device that looks like something you'd find on the shelf at Home Depot. You wouldn't want to see one coming at you, but if you needed one, you'd likely be in such bad shape that you wouldn't even notice. The devices, which typically cost about $300 each, are used to access the marrow and vascular system inside bones when a patient's veins have collapsed or are inaccessible. They're standard features in most American ambulances and emergency rooms. But in developing countries like India, where the need is huge, that $300 price is an insurmountable hurdle to widespread adoption. And therein lies an opportunity. What if you could design a low-cost device to do the same job, without the bells and whistles that make conventional ones expensive? That's exactly the kind of challenge that gets the fellows of the Stanford India Biodesign (SIB) team excited. The program, a partnership with the Indian government started in 2007, is based at Stanford and in New Delhi at the Indian Institute of Technology and the All India Institute of Medical Sciences. Each year, four Indian fellows interested in medical-technology design and development go to Palo Alto for six months to learn the basics of the Stanford-created biodesign process. They then head back to India, fanning out to observe medical care in both high-volume urban hospitals and rural clinics. Their mandate: Draw up a list of patient-care needs that might be solved with better devices.
The model of ideas bubbling up from developing countries is relatively new.That model, where ideas for new products bubble up from clinical practices observed in developing countries, is a relatively new one. Typically, big companies would consult practicing doctors for suggestions, but that only got them so far. "Physicians are generally good at identifying incremental problems, suggesting, for example, a change in a handle," but not good at imagining breakthrough technologies, says Dr. Rajiv Doshi, the U.S. executive director of SIB and a consulting assistant professor in the Department of Medicine at Stanford. Instead, revolutionary American innovations tend to come from startups, which -- driven by market dynamics -- introduce products to the developing world at high prices. But in 2009, GE flipped that model on its head when it introduced a $1,000 electrocardiogram device and a $15,000 portable ultrasound machine that it had developed in rural India and in rural China, respectively. That new paradigm, dubbed "reverse innovation," has the promise not just to bring lifesaving technologies to developing countries but also to establish lower price points for products in existing markets -- and, presumably, to generate a healthy stream of sales in both markets. The Stanford program hopes to further that idea by combining its fellows' Indian experience with its Stanford-trained biodesign expertise, to generate a list of problems that demand better devices. The list is then vetted to focus on problems that are both urgent and scalable, have the potential for a big impact, and present good business opportunities. In the case of the bone drill, the fellows were able to develop rough, functioning prototypes. But then they hit a wall. They realized they needed more sophisticated engineering and design help than they could get in India. "The Indians knew they could benefit from having a world-class group optimize the [bone drill's] engineering and think about the user interface," Doshi says. "The device needed to be disposable, have a low part count, be inexpensive, easily assembled, capable of being used by a poorly trained person, and able to be manufactured cheaply in India." Doshi pointed the group to Lunar Design, a San Francisco industrial-design firm. "I told the Lunar team, 'Here are the requirements. I know you're at full capacity, but this is important. And here's a timeline that isn't achievable.' " This wasn't the first time the designers at Lunar had worked with Doshi, who is also the founder and chief scientific officer of device manufacturer Ventus Medical. Lunar had tackled a similar issue with a low-cost sleep-apnea device it had previously codeveloped for Ventus. For that product (which won an IDEA gold award in 2010), instead of developing a ne plus ultra gadget, the team focused on a lower-cost solution that would work for most potential users, but not all of them. It's what the industry calls the "best value" solution, not the "best possible" one. That's a sensible -- but radical -- notion. "The approach in the U.S. is to come in with big guns and solve a problem with a device that always works for every person, in every situation, even if it costs more," says Lunar president John Edson. "That is the model that has been rewarded by payers." But as GE's experience illustrates, that is no longer the sole model -- not just because of the potential of emerging markets but also because of the skyrocketing cost of health care everywhere. So Lunar engineered its bone drill to work manually rather than on expensive batteries. It stripped out nonessential features and made sure the drill could be operated with only two hands. The collaboration benefited both sides. The Indians got access to Silicon Valley's sophisticated engineering and device-development ecosystem, and the California team got a ramped-up design process, thanks to the relative ease of testing in India. "There's a lot more red tape in the U.S.," says Lunar's Matt Durack. "This device can only prove out on human bones, and we were able to take months out of the process because of faster access to cadavers in India." The teams collaborated over Skype and shipped prototypes back and forth via FedEx. Eventually, they created a device that would sell for around $20, with no drop in efficacy. There are still many hurdles before the device will be available commercially. For one thing, designers have yet to crack the code on making sure the drill is not reusable, a big issue in India where blood-borne diseases are often spread with reusable devices. And even if the device clears regulatory hurdles in India, it will be a while before it could pass the FDA here and circumvent lobbyists' resistance to cheaper devices. But the collaborative-development model -- taking advantage of the best opportunities in each culture -- has the potential to up-end device development and boomerang back with benefits for health care on both sides. And the SIB program is training the trainers of the future. "The power of precedent is extraordinary," says Doshi. "If we're successful, we'll have created not just a device but a model that others can replicate. This team understood the need and created something socially impactful. It's what designers love to do."
A version of this article appears in the July/August 2011 issue of Fast Company.[Top image courtesy ABC Family]